During Tuesday’s Current trade, Shares of Esperion Therapeutics Inc(NASDAQ:ESPR), lost -0.63% to $47.65.
Esperion Therapeutics, Inc. (ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, recently offered ETC-1002 (bempedoic acid) development program updates and financial results for the second quarter ended June 30, 2015.
Development Program and Company Highlights
- June 15, 2015: Dr. Mary McGowan designated Chief Medical Officer, and Dr. Scott Braunstein elected to the board of directors.
- July 7, 2015: Removal of the 240 mg partial clinical hold by the FDA, allowing ETC-1002 to be used at doses above 240 mg in clinical studies.
- July 28, 2015: Positive top-line Phase 2 results declared for ETC-1002-014 in patients with both hypercholesterolemia and hypertension.
- July 30, 2015: Second annual analyst and investor day.
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products comprise ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, in addition to to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies.
Shares of Mizuho Financial Group Inc. (ADR) (NYSE:MFG), declined -4.17% to $3.91, during its current trading session.
Mizuho Securities USA (MSUSA), the U.S. investment banking partner of Mizuho Financial Group (NYSE: MFG), has designated Eric Shenker Managing Director and Head of US Equity Trading, declared John Koudounis, President and CEO.
“Eric is a highly practiced trader and skilled executive with a distinguished career on Wall Street,” Koudounis said. “MSUSA continues to attract high-caliber talent as we proceed with the expansion of our US equity sales, trading and research platform. He will be an invaluable addition to the firm.”
Shenker comes to MSUSA with more than 20 years on Wall Street in senior trading positions. He joins the firm from CRT Capital Group, where he served as Head of Equities and Head of Equity Trading. Most recently, he was Senior Vice President and Head of Americas Equity Trading at Alliance Bernstein LP. Formerly, he was a partner at Bascom Hill Partners, New York, where he assisted in building the firm’s long/short equity trading fund and oversaw the trading desk.
Mizuho Financial Group, Inc. engages in banking, trust banking, securities, and other businesses related to financial services in Japan, the Americas, Europe, and Asia/Oceania not taking into account Japan. The company offers deposits, housing loans, investment trusts, and individual insurance products, in addition to handles trust products as an agent; and retail banking solutions compriseing of consulting services of business succession and asset inheritance and asset administration for business owners and high-net-worth customers.
Centurylink Inc (NYSE:CTL), during its Tuesday’s current trading session decreased -2.81% to $26.28.
CenturyLink, Inc. (CTL) declared its plans for a multi-city tour featuring industry analysts and select CenturyLink customers and executives to share technology insights and lessons learned with enterprise IT leaders about big data, cloud, security and customer-centric IT.
The Elevate events provide an opportunity for CenturyLink customers, prospects and partners to learn from industry experts about topics important to the disruption taking place in IT recently. The series is co-sponsored by Alcatel Lucent and features CIO Magazine as a media partner.
The series kicks off in Boston on July 15 and continues in key North American and global markets through October 2015. The roundtable forums feature keynotes from leading industry experts, counting CIO Magazine contributing editor Julia King, “Cloudonomics” author Joe Weinman and CenturyLink executives Shirish Lal, David Shacochis, David Mahon and Gary Gauba.
CenturyLink, Inc. provides various communications services to residential, business, governmental, and wholesale customers in the United States. It operates through two segments, Business and Consumer. The company offers broadband services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; private line services for transmission of large amounts of data between sites; and multi-protocol label switching, a data networking technology to support real-time voice and video.
Finally, Celgene Corporation (NASDAQ:CELG), decreased -0.37%, to $117.64.
Celgene Corporation (CELG) plans to present at three forthcoming investor conferences in September where Celgene administration will provide an overview of the Company. The conferences will be webcast live and a link to the webcast will be accessible in the Investor Relations section of the Company’s website at www.celgene.com.
Wednesday, September 9, 2015 at Baird’s 2015 Healthcare Conference in New York City at 3:45 pm ET.
Wednesday, September 16, 2015 at the 2015 Morgan Stanley Global Healthcare Conference in New York City at 1:40 pm ET.
Thursday, September 17, 2015 at the 2015 Bank of America Merrill Lynch Global Healthcare Conference in London at 8 am ET.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
